The use of SGLT2 inhibitors has been identified as a protective factor for AKI in several studies (CREDENCE [Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation], DECLARE-TIMI-58 [Dapagliflozin Effect on Cardiovascular Events], CANVAS [Canagliflozin Cardiovascular Assessment Study], and EMPA-REG) with a relative risk reduction of AKI of 0.75 (95% CI 0.66–0.85)35. This evidence concerns the gene SLC5A2 and kidney disorder.